RxDoctor Payments Data

Stephen Lewis, MD

Neurology · Ft Washinton, PANPI 1942289566

Payments from drug & device makers

$5,935in general payments, 2019–2025

Across 325 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$937
  • UCB, Inc.$814
  • SK Life Science, Inc.$631
  • AbbVie$488
  • Neurocrine Biosciences, Inc.$282
  • Strongbridge US Inc.$279
  • plus $3K from 35 others

What the payments were for

  • Consulting fees$60010%
  • Speaking & faculty fees$361%
  • Food & beverage$5,30089%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,935 in reported general payments places this provider in the 65th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$87,922
Medicare patients
185
Services billed
732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5056$762,844
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$461,339
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5018$320,451
BriviactBrivaracetam67$121,563
Rufinamide12$35,902
KeppraLevetiracetam19$29,025
QuliptaAtogepant26$27,381
TopamaxTopiramate12$21,785
Emgality PenGalcanezumab-Gnlm30$20,787
FycompaPerampanel13$20,404
Glatiramer Acetate11$19,032
Aimovig AutoinjectorErenumab-Aooe16$16,851
Divalproex Sodium146$16,061
Aripiprazole33$11,210
Lacosamide66$10,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Dilantin$174$768,44492 claims
CSL BehringPrivigen$158$320,45118 claims
UCB, Inc.Briviact$814$121,56367 claims
AbbVieQulipta$488$27,38126 claims
Eisai Inc.Fycompa$232$20,40413 claims
Neurocrine Biosciences, Inc.Ongentys$282$9,45215 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$54$4,37813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Ft Washinton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →